Authors
Zemin Dou, Yongfang Xie, Shichao Yan, Xue Sun, Yangyang Han, Tingting Feng, Guohui Wang
Published in
Nanomedicine (London, England). Pages 1-15. Nov 12, 2026. Epub Nov 12, 2026.
Abstract
In castration-resistant prostate cancer (CRPC), the benefit of androgen receptor signaling inhibitors, taxanes, poly(ADP-ribose) polymerase (PARP) inhibitors, and immunotherapy is limited by systemic toxicity, molecular heterogeneity, biomarker-restricted efficacy, and prior therapy cross-resistance. These limitations undermine long-term disease control, particularly when tumoral drug distribution, intracellular retention, or multi-agent co-delivery is suboptimal. This review outlines major resistance mechanisms and their impact on current systemic regimens. It then introduces mesoporous polydopamine (MPDA) as a versatile nanoplatform with high drug-loading capacity, facile surface functionalization, photothermal responsiveness, and compatibility with combinatorial regimens. Reported PC-3 experiments include approximately 53% cell death with AS1411-targeted MPDA/docetaxel plus irradiation versus 25% without irradiation, and representative Annexin V/propidium iodide double-positive fractions of 85.9% with irradiated MPDA-mediated docetaxel/small interfering RNA co-delivery versus 39.5% with free docetaxel.
PMID:
43016294
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0